Just to close the loop and I checked the Sept 3, 2013 press release re ASSURE and I found the -1.43% percent atheroma volume (PAV) for patients treated with Crestor (rousuvastatin) and this change was significant at the p<0.002 level i.e. highly significant an not just a random event. From what I understand is that this change is Crestor only (control) vs Crestor + rvx-208. That is great news. There was also a number of highly significant positive findings.

It sure supports the BoM trial. Old news but a reminder for me.

Thanks to those reposting the RVX list achievements and to BDAZ for pointing out the variances vs. recent presentations.

As GAC pointed out RVX has a track record for over promise and under deliver. Let's hope for the positive this time.

Narmac I like your comment re the investor conferences - "Dont think for one moment those with big wallets dont ask DM the tuff questions!!,,They dont buy in on DMs muffled political answers! And the "we are really excited here at RVX" pitch probably just dont cut the mustard!!!"

• Boy, that says it all.

I've been very cynical lately and I don't like being that way so I'll say on the positive side RVX has had many very positive achievements in 2017 and the start of 2018 and I firmly believe lots more to come IMHO.

I like the RVX press release. It is clear and concise. It is the combination now of the speed of science combined with the lack of significant funding to get trials moving that leaves me in an uncertain mood and I don't feel reassured about the size and speed of funding. I realize that the science will have delays. That is just the way science is. But if they had a solid war chest right now then all the other trials could get moving.

Oh well, it is what it is. It must be tough to be in Don's position with a financial vice tightening on your temples a little bit more each day.

GLTA and I hope the conference goes well.

Toinv